Cargando...
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
In myeloproliferative neoplasms (MPNs) the incidence of venous thromboembolism (VTE) is 0.6–1.0 per 100 pt-years, and the rate of recurrence after VTE is 6.0–6.5 per 100 pt-yrs. Vitamin K-antagonists (VKA) reduces the risk of recurrence after VTE at usual sites (i.e., deep venous thrombosis (DVT) of...
Guardado en:
| Publicado en: | Blood Cancer J |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6018810/ https://ncbi.nlm.nih.gov/pubmed/29946112 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0101-8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|